The world’s leader in fighting ovarian cancer

OCRA
ovarian cancer research alliance

ANNUAL REPORT 2019
Dear friends,

As we look back on all that we accomplished in 2019, we are reminded of just how important this work is, and how grateful we are for you, our supporters.

So much of what we accomplished this year was due to your generosity. We are propelled by everything we have learned, and continue to learn, from the ovarian cancer community—those touched by the disease and those searching for answers. And we remain steadfast to our mission: to cure ovarian cancer, advocate for patients and support survivors and their families.

OCRA is the largest non-government funder of ovarian cancer research and has invested more than $100 million in crucial research. OCRA fights ovarian cancer on all fronts, including in the lab and on Capitol Hill, and through innovative programs to support survivors and their families.

We are pleased to share these highlights with you, which are just a brief overview of the breadth of our work. We invite you to visit our website (ocrahope.org) or follow us on social media (@ocrahope) to stay up to date on all the latest we have to share.

On behalf of everyone at OCRA, thank you!

Sincerely,

Audra Moran
President & CEO
RESEARCH

PARTNERING WITH SCIENTISTS TO ERADICATE OVARIAN CANCER

OCRA is the largest non-government funder of ovarian cancer research and has the longest track record of impact. We have invested more than $100M to jumpstart promising research and hasten desperately needed breakthroughs. Every day, OCRA-funded researchers are finding new ways to treat, prevent and, ultimately, cure ovarian cancer.

2019 OCRA GRANTEES:

In 2019, OCRA-funded researchers made many discoveries that advanced the field of ovarian cancer research. They found that stem-like cells may be key to preventing recurrence; worked to increase efficacy of PARP inhibitors; identified genes associated with increased risk of ovarian cancer; revealed new drug therapy combinations; and investigated new approaches to using immune therapy to combat ovarian cancer.
COLLABORATIVE RESEARCH DEVELOPMENT GRANT

Ronald Buckanovich, MD, PhD  
*Magee-Womens Research Institute*  
Targeting Tumor Desmoplasia to Enhance Immunotherapy

Rugang Zhang, PhD  
*The Wistar Institute*  
Developing Epigenetic Therapies for Ovarian Cancer

LIZ TILBERIS EARLY CAREER AWARD

Min Soon Cho, PhD  
*MD Anderson Cancer Center*  
The Role of Platelet in the Regulation of Immune Response to Ovarian Cancer

Zihua Gong, MD, PhD  
*Cleveland Clinic*  
DNA Repair Pathways as Targets for Therapy-Resistant Ovarian Cancer

Xiaowen Hu, PhD  
*University of Pennsylvania*  
Targeting Chromatin Remodeling Complex to Treat Ovarian Cancer

Kate Lawrenson, PhD  
*Cedars-Sinai Medical Center*  
Elucidating the Role of SOX17 in HGSOC

Elizabeth Stover, MD, PhD  
*Dana Farber Cancer Institute*  
Targeting Anti-apoptotic Proteins BCL-XL and MCL-1 in Serous Ovarian Cancer

Takemasa Tsuji, PhD  
*Roswell Park Comprehensive Cancer Center*  
Utilization of Tumor-recognizing CD4+T Cells in Cancer Immunotherapy

Kris Wood, PhD  
*Duke University*  
Precision Targeting of Altered Mitochondrial States in Ovarian Cancer
ANN AND SOL SCHREIBER
MENTORED INVESTIGATOR AWARD

Kristin G. Anderson, PhD  
*Fred Hutchinson Cancer Research Center*  
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer

Alexander Cole, PhD  
*Magee-Womens Research Institute*  
Investigating Regulators of Quiescence in Epithelial Ovarian Cancer

Sarah Gitto, PhD  
*University of Pennsylvania*  
Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer

Guy Katz, MD, PhD  
*MD Anderson Cancer Center*  
Therapeutic miRNA Targeting for Ovarian Cancer

Isaac Klein, MD, PhD  
*Dana Farber Cancer Institute*  
Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer

John Krais, PhD  
*Fox Chase Cancer Center*  
Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer

Marilyne Labrie, PhD  
*Oregon Health and Science University*  
Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer

Jing Li, MD, PhD  
*University of Michigan*  
ARID1A Drives Ovarian Cancer Immunotherapy

Shariska Petersen, MD  
*University of Kansas Medical Center Research Institute*  
Cyclin E and BRD4 as Markers for a New PARPi Drug Combination
Alba Rodriguez-Garcia, PhD  
*University of Pennsylvania*  
Targeting MISIIIR with CAR T Cells for the Treatment of Ovarian Cancer

Elaine Stur, PhD  
*MD Anderson Cancer Center*  
Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer

Shuai Wu, PhD  
*The Wistar Institute*  
Synthetic Lethality for ARID1A Mutation in Ovarian Cancer

Haineng Xu, PhD  
*University of Pennsylvania*  
A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers

Zvi Yaari, PhD  
*Memorial Sloan Kettering Cancer Center*  
Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer
We are the voice for the ovarian cancer community, working with legislators to ensure federal ovarian cancer research and education, patient safety, and access to high-quality care are protected on Capitol Hill. We also change the way future healthcare professionals recognize ovarian cancer through our Survivors Teaching Students program.

In 2019, 86 ovarian cancer advocates from 37 states gathered in Washington, DC to meet with their elected officials and ask them to sign onto an effort to dramatically increase funding for the Ovarian Cancer Research at the Department of Defense.

Our Advocate Leaders program grew from 36 members to 50 members representing 35 states and the District of Columbia. We helped craft legislation to reauthorize Johanna’s Law, the Gynecologic Cancer Education and Awareness Act that, once enacted, will allow the program to expand and reach more people across the country. Our targeted legislative campaigns helped influence the federal government to spend a record amount of funds in support of ovarian cancer research and awareness programs.

Survivors Teaching Students trained 142 volunteers who joined forces with a total of 998 committed individuals who shared their stories of diagnosis and treatment with 12,994 rising medical professionals at 327 schools and institutions around the U.S.
PATIENT SUPPORT
STANDING TOGETHER WITH EVERY PERSON TOUCHED BY THE DISEASE

Our programs help people navigate an overwhelming diagnosis, supporting patients and their families when and where they need it the most. Our Woman to Woman peer support program pairs newly diagnosed patients with survivors who provide hope and insight, and our Ovarian Cancer National Conference brings survivors together to share knowledge and build community.

In 2019, OCRA brought in an oncology social worker who, in one year, fielded calls from 419 patients and trained 13 Woman to Woman mentors. Furthermore, OCRA awarded two grants for new Woman to Woman program sites, bringing the total number of sites funded to 43. Our oncology social worker also oversaw the growth of our Inspire Online Community, which boasted 54,757 members.

Our Ovarian Cancer National Conference was held in Seattle, and welcomed nearly 400 attendees from across the U.S.—and as far away as Australia!—who came together to delve into an array of topics and build community.
FUNDRAISING
BUILDING A COMMUNITY OF THOSE COMMITTED TO A CURE

A variety of events were held across the U.S. with a singular purpose: raise vital funds to support ovarian cancer research. Ranging from fitness to fashion, comedy to culinary, these events—produced by OCRA and by third parties—raised more than $1.5 million.

STAND UP FOR MADELINE
May 20, 2019
A hilarious evening for a serious cause, celebrating the life of legendary funny lady, Madeline Kahn with New York City’s top comedians at Carolines on Broadway.

HOPE FASHION SHOW
Dallas, TX, September 19, 2019
OCRA’s first Hope Fashion Show, sponsored by Stanley Korshak, brought together local celebrities and fashion lovers to raise awareness, money and, just as importantly, hope.
OCRA HEROES

Whether it’s a lemonade stand or dance-a-thon, anyone can be a hero. OCRA heroes are everyday people doing extraordinary things like Barbara Gallagher, who climbed mountains (literally and figuratively) to reach new heights while raising awareness for ovarian cancer research.

OVARIAN CYCLE

OCRA’s series of indoor cycling events are the perfect way to work out, have fun and raise money for ovarian cancer research! Rides were held across the country, from San Mateo to Detroit, LA to Tampa, and everywhere in between.

TURN UP THE HEAT DC

March 5, 2019

OCRA’s signature foodie event, hosted by Elle Simone of America’s Test Kitchen, featured a private VIP reception sponsored by United Airlines and culinary delights from Washington, DC’s top women chefs and mixologists.

Elle Simone, Audra Moran, and the 2019 CHEF ON FIRE Seng Luangrath of THIP KHAO
TURN UP THE HEAT BOSTON  
Tuesday, April 30, 2019

Guests enjoy an evening of drinks and bites from Boston’s top female chefs and mixologists at Catalyst Restaurant in Cambridge.

STYLE LAB  
November 6, 2019

A dazzling evening hosted by Maggie Gyllenhaal and Kate Mara, and sponsored by InStyle magazine, featured a live musical performance from En Vogue, fashion from top designers, exclusive personalized Style Lab experiences and a one-of-a-kind celebrity auction... all to support research and a cure for ovarian cancer.
BOARD OF DIRECTORS / NATIONAL LEADERSHIP COUNCIL

EXECUTIVE COMMITTEE
John W. Hansbury, Esq., Chair
Robin S. Cohen, Vice President
Jennifer McCahill, Treasurer
Dana L. Mark, Esq., Secretary
Tom Liebman, Director
Matthew Neal Miller, Director
Patricia Goldman
Carol J. Hamilton
Caroline Hirsch
Veronica Jordan, PhD
Edward Labaton, Esq.
Ylai G. Mayer
Chris Newcomb
John Orrico
Lisa Schreiber
Elle Simone Scott
Chris Tilberis
Robin Zarel

BOARD MEMBERS
Mona Baird
Susan D. Bazaar
Jeannette Chang
Carmel J. Cohen, MD
Mei-Li da Silva Vint, Esq.
Andrew Feuerstein, Esq.
Shelley Golden

NATIONAL LEADERSHIP COUNCIL
Judith Abrams
Terri McKnight, CPA
Diane Rader O’Connor
SCIENTIFIC ADVISORY COMMITTEE

Beth Karlan, MD, CHAIR (2019–present)
UCLA Medical Center, Los Angeles, CA

Ronald Alvarez, MD (2016–present)
Vanderbilt University Medical Center, Nashville, TN

Deborah Armstrong, MD (2016–present)
Johns Hopkins School of Medicine, Baltimore, MD

Robert C. Bast Jr., MD (1997–present)
MD Anderson Cancer Center, Houston, TX

Andrew Berchuck, MD, (2000–present)
Duke Comprehensive Cancer Center, Durham, NC

Jonathan S. Berek, MD, MMS (1997–present)
Stanford University School of Medicine, Palo Alto, CA

Molly Brewer, DVM, MD, MS (2004–present)
University of Connecticut Health Center, Farmington, CT

Ronald Buckanovich, MD, PhD (2013–present)
Magee-Womens Research Institute, Pittsburgh, PA

Robert Coleman, MD (2016–present)
MD Anderson Cancer Center, Houston, TX

Alan D’Andrea, MD (2017–present)
Dana-Farber Cancer Institute, Boston, MA

Ronny I. Drapkin, MD, PhD (2011–present)
University of Pennsylvania, Philadelphia, PA

Annie Ellis (2016–present)
Patient Advocate

Ellen Goode, PhD (2019–present)
Mayo Clinic, Rochester, MN

Dineo Khabele, MD (2015–present)
Washington University School of Medicine, St. Louis, MO

Ernst Lengyel, MD, PhD (2013–present)
University of Chicago, Chicago, IL

Douglas Levine, MD (2010–present)
New York University Langone Health, New York, NY

Ursula Matulonis, MD (2014–present)
Dana-Farber Cancer Institute, Boston, MA

Kenneth Nephew, PhD (2014–present)
Indiana University Simon Cancer Center, Bloomington, IN

Celeste Leigh Pearce, PhD, MPH (2015–present)
University of Michigan, Ann Arbor, MI

Kunle Odunsi, MD, PhD (2014–present)
Roswell Park Comprehensive Cancer Center, Buffalo, NY

Sandra Orsulic, PhD (2011–present)
UCLA David Geffen School of Medicine, Los Angeles, CA

Daniel Powell Jr., PhD (2015–present)
University of Pennsylvania, Philadelphia, PA

Stephen Rubin, MD (2000–present)
Fox Chase Cancer Center, Philadelphia, PA

Carolyn D. Runowicz, MD (1997–present)
Florida International University, Miami, FL

Ie-Ming Shih, MD, PhD (2013–present)
Johns Hopkins University School of Medicine, Baltimore, MD

Anil Sood, MD (2016–present)
MD Anderson Cancer Center, Houston, TX

Shelley Tworoger, PhD (2019–present)
Moffit Cancer Center, Tampa, FL
STAFF

Audra Moran
President & CEO

Bibi Ali
Vice President, Finance

Leslie Almiron
Associate Director, Finance

Jorge Calderon
Associate, Finance

Jake Carlin
Manager, Development & Events

David Carroll
Manager, Database

Erin Cassin
Manager, Social Media & Content

Vanessa Cramer
Director, Policy

Sarah DeFeo
Vice President, Scientific Affairs

Candice Harrison
Associate Manager, Development & Events

Rohan Jyothinagaram
Assistant, Programs & Operations

Odia Kane
Kolker Fellow

Jason Lalonde
Manager, Development & Events

Deb Levy
Vice President, Marketing & Communications

Kim Liao
Associate, Development

Erin Merkl
Assistant, Operations

Chad Ramsey
Vice President, Policy

Nikki Wargo
Senior Director, Events & Corporate Partnerships

Lindsey Weeks
Director, Digital Communications

Jon Zeidman
Vice President, Development

(Staff listed are current as of 12/21/2020)
# FINANCIAL STATEMENT

## 2019

### Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue &amp; Support</td>
<td>$7,418,256</td>
</tr>
<tr>
<td>Investment income, net</td>
<td>$3,331,069</td>
</tr>
<tr>
<td><strong>Total Revenue, Support &amp; Investments</strong></td>
<td><strong>$10,749,325</strong></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>$6,746,090</td>
</tr>
<tr>
<td>Conference</td>
<td>$633,745</td>
</tr>
<tr>
<td>Education, Support and Advocacy</td>
<td>$1,653,173</td>
</tr>
<tr>
<td><strong>Total Program Services</strong></td>
<td><strong>$9,033,008</strong></td>
</tr>
<tr>
<td>Fundraising</td>
<td>$1,212,262</td>
</tr>
<tr>
<td>Administrative</td>
<td>$940,941</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$11,186,211</strong></td>
</tr>
<tr>
<td><strong>Ending Net Assets</strong></td>
<td><strong>$18,999,892</strong></td>
</tr>
</tbody>
</table>